To the Editor—we read with great interest the article by Magleby and colleagues entitled “Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019” [1]. This article adds to the growing body of work on using the polymerase chain reaction (PCR) cycle threshold (Ct)-value associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA detection in clinical specimens as a prognostic indicator and to establish criteria for active infection and transmissibility. Although we recognize the importance of studying laboratory results and their relevance to care of patients with coronavirus disease 2019 (COVID-19), we wish to inform your readers of potential caveats that must be considered when applying published findings regarding Ct-values to their own patients’ results.

1) Specimen collection method, specimen source, transport media type and volume, duration from specimen collection to analysis, and days from infection to specimen collection can all impact the amount of viral RNA that could be detectable by an assay, and these variables are reflected in the Ct values.

2) No quantitative SARS-CoV-2 assays have received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA). Additionally, no international, commutable standardized reference material is currently available, which would be needed for validation of quantitative assays that generate comparable results across manufacturers and laboratories. Although specimens with lower Ct-values generally have more viral RNA than specimens with higher Ct-values, the quantitation and precision associated with those differences in Ct-values have not been determined.

3) Only traditional real-time PCR assays produce a Ct-value. Some diagnostic assays used to detect SARS-CoV-2 RNA use isothermal amplification methods, which do not produce a Ct-value. Other PCR platforms use nested PCR, which is not designed for quantitative interpretation.

4) Ct-values can vary significantly between and within methods. The College of American Pathologists (CAP) recently surveyed more than 700 laboratories using proficiency testing material produced from the same batch (Figure 1). The median Ct-values reported by the instruments for different FDA EUA methods varied by as much as 14 cycles. Within a single test performed on the same instrument, the difference in the median Ct-values for different targets was as high as 3.0 cycles. Finally, within a single gene target for a single method, up to 12.0 cycle differences were seen across all laboratories. The assay and gene target used by Magleby et al, ORF1a detected by the Roche cobas system, differed by approximately 6.0 cycles across all laboratories responding to the survey. Many clinical laboratories are using multiple tests that assess different gene targets for SARS-CoV-2 and are performing testing on different platforms. This adds to the potential variability of Ct-values produced by a single laboratory.

The ongoing shortage of commercial testing reagents presents a major obstacle to conducting large research studies comparing testing platforms. We thus believe that data from the CAP proficiency testing survey...
are extremely valuable in advancing our understanding of Ct-value commutability in SARS-CoV-2 molecular testing. If healthcare providers and researchers attempt to employ Ct-values as a component of their patient assessment, we caution them to consider the points described in this letter.

Notes

Acknowledgments. This Letter is submitted with approval from the College of American Pathologists.

Potential conflicts of interest. N. W. A. reports being on the Scientific Advisory Board of Diasorin Molecular; F. S. N. reports honoraria from Abbott Molecular; D. R. reports receiving research funding on novel antibacterial agents through Shionogi Inc., Turfase pharmaceuticals Inc., and VenatoRx pharmaceuticals; grants from BD, Roche, BioFire, and OpGen; Advisory Board for Luminex; and speaker fees for BD; R. C. S. reports honoraria from BioFire. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Daniel Rhoads,1 David R. Peaper,2 Rosemary C. She,3 Frederick S. Nolte,4 Christina M. Wojewoda,4 Neil W. Anderson,5 and Bobbi S. Pritt1

1Cleveland Clinic, Cleveland, Ohio, USA, 2Yale School of Medicine, New Haven, Connecticut, USA, 3Keck School of Medicine of the University of Southern California, Los Angeles, California, USA, 4Medical University of South Carolina, Charleston, South Carolina, USA, 5University of Vermont Medical Center, Burlington, Vermont, USA, 6Washington University, St. Louis, Missouri, USA, and 7Mayo Clinic, Rochester, Minnesota, USA

References


Correspondence: B. S. Pritt, Mayo Clinic, 200 First St SW, Division of Clinical Microbiology, Rochester, MN 55905, USA (pritt.bobbi@mayo.edu).

Clinical Infectious Diseases® 2020
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
For permissions, e-mail: journals.permissions@oup.com.
DOI: 10.1093/cid/ciaa1199